Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.


Subscribe or Register

Existing user? Login

PJ Online | News: "Cooling off" period no benefit in ACS

Home > PJ (current issue) > News / Daily News | Search

Return to PJ Online Home Page

The Pharmaceutical Journal
Vol 269 No 7226 p772
30 November 2002

This article

News summary

Related websites
American Heart Association (more)

"Cooling off" period no benefit in ACS

Patients with acute coronary syndromes at high risk of heart attack or stroke do not benefit from extended antithrombotic treatment before angioplasty, according to data presented at the American Heart Association scientific sessions in Chicago last week.

A group of 410 patients with unstable coronary syndromes were given extended antithrombotic pre-treatment (72?120 hours) or early intervention with pre-treatment for less than six hours. All received the same antithrombotic treatment ? aspirin, clopidogrel (Plavix) and heparin.

After 30 days, three deaths and 21 non-fatal myocardial infarctions had occurred in the cooling-off group, compared with no deaths and 12 myocardial infarctions in the early intervention group (relative risk 2.0, 95 per cent confidence interval, 1.01?3.94, P=0.04). After catheterisation, 11 events (death or MI) had occurred in each group.

Study lead Dr Franz-Josef Neumann, Bad Krozingen Heart Centre, Germany, said: "This means that we cannot detect an effect of pre-treatment on risk reduction for the subsequent intervention. Pre-treatment is not needed and even increases the risk to patients."

Back to Top

Home | Journals | News | Notice-board | Search | Jobs  Classifieds | Site Map | Contact us

©The Pharmaceutical Journal

Citation: The Pharmaceutical Journal URI: 20008273

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

RPS publications

Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.


Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Rate
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.